Structure

InChI Key ZOCKGBMQLCSHFP-KQRAQHLDSA-N
Smile CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
InChI
InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C34H36F3NO13
Molecular Weight 723.65
AlogP 2.46
Hydrogen Bond Acceptor 13.0
Hydrogen Bond Donor 5.0
Number of Rotational Bond 10.0
Polar Surface Area 215.22
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 51.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA inhibitor DailyMed Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Carcinoma in Situ 3 D002278 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Renal and urinary disorders
18.7
General disorders and administration site conditions
17.67
Injury, poisoning and procedural complications
15.44
Nervous system disorders
8.75
Surgical and medical procedures
6.86
Skin and subcutaneous tissue disorders
5.32
Gastrointestinal disorders
5.15
Psychiatric disorders
3.26
Infections and infestations
2.92
Vascular disorders
2.92
Investigations
2.74

Cross References

Resources Reference
CAS NUMBER 56124-62-0
ChEBI 135876
ChEMBL CHEMBL1096885
DrugBank DB00385
DrugCentral 2805
EPA CompTox DTXSID9046497
FDA SRS 2C6NUM6878
PubChem 454216
SureChEMBL SCHEMBL12824
ZINC ZINC000049783788